Elly | $8,000,000 | (Feb 26, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)
Abram Scientific | $11,750,000 | (Feb 26, 2026)
Ultromics
United Kingdom
- Oxford, Oxfordshire
- 31/07/2025
- Series C
- $55,000,000
Ultromics pioneers precision heart failure detection. Our groundbreaking platform, EchoGo®, is revolutionizing the diagnosis of heart failure using artificial intelligence and cardiac ultrasound. Our technology empowers clinicians to make precise, efficient, and accurate assessments, drawing from the largest known heart disease dataset in echocardiography. We target challenging cardiac diseases, starting with HFpEF, to support timely diagnosis and early intervention. In collaboration with the Mayo Clinic, Johnson & Johnson, and Pfizer, we are continuously developing innovative diagnostic tools aimed at halting the progression of heart failure.
Learn more: https://www.ultromics.com/.
Follow Ultromics on social media for the latest news, X: https://x.com/ultromics, LinkedIn: https://www.linkedin.com/company/ultromics/.
- Industry Hospital & Health Care
- Website https://www.ultromics.com/
- LinkedIn https://www.linkedin.com/company/ultromics/
Related People
Ross Upton, PhDFounder
United Kingdom -
Greater Oxford Area
Founder, CEO & Chief Scientific Officer, Ultromics
Clinical Researcher, University of Oxford
AI Co-Chair, HeartShare, NIH
Allica Bank | $155,000,000 | (Feb 26, 2026)
Quill Meetings | $6,500,000 | (Feb 26, 2026)
Avisi Technologies | $10,700,000 | (Feb 26, 2026)
TBD | $3,000,000 | (Feb 26, 2026)
NationGraph | $18,000,000 | (Feb 26, 2026)
Cicada | $13,500,000 | (Feb 26, 2026)
Centauri Therapeutics Limited | $8,107,170 | (Feb 25, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)